GRK2 as a novel gene therapy target in heart failure

Journal of Molecular and Cellular Cardiology

Volumn 50, Issue 5, 2011, Pages 785-792

  Rengo, Giuseppe ^a,b,d   Lymperopoulos, Anastasios ^a,c   Leosco, Dario ^d   Koch, Walter J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b IRCCS   (Italy)

^c NOVA SOUTHEASTERN UNIVERSITY   (United States)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

adrenergic receptor; ARKct; G protein coupled receptor kinase; Gene therapy; Heart failure; Neurohormonal feedback

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR KINASE; G PROTEIN COUPLED RECEPTOR KINASE 2; METOPROLOL; PARVOVIRUS VECTOR;

ADRENAL GLAND; CARDIOMYOPATHY; CARDIOVASCULAR RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; ENZYME INHIBITION; GENE ACTIVITY; GENE FUNCTION; GENE OVEREXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; HEART FAILURE; HEART INFARCTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; REVIEW; TREATMENT RESPONSE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; G-PROTEIN-COUPLED RECEPTOR KINASE 2; GENE THERAPY; HEART FAILURE; HUMANS; MODELS, BIOLOGICAL;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 79953685595     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2010.08.014     Document Type: Review

References (68)

1. Hunt S.A., Abraham W.T., Chin M.H., Feldman A.M., Francis G.S., Ganiats T.G., et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119:e391-e479.
2. Williams M.L., Koch W.J. Viral-based myocardial gene therapy approaches to alter cardiac function. Annu Rev Physiol 2004, 66:49-75.
3. Vinge L.E., Raake P.W., Koch W.J. Gene therapy in heart failure. Circ Res 2008, 102:1458-1470.
4. Hajjar R.J., Zsebo K., Deckelbaum L., Thompson C., Rudy J., Yaroshinsky A., et al. Design of a phase 1/2 trial of intracoronary administration of AVV1/SERCA2a in patients with heart failure. J Card Fail 2008, 14:355-367.
5. Jaski B.E., Jessup M.L., Mancini D.M., Cappola T.P., Pauly D.F., Greenberg B., et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail 2009, 15:171-181.
6. Lai N.C., Roth D.M., Gao M.H., Tang T., Dalton N., Lai Y.Y., et al. Intracoronary adenovirus encoding adenylyl cyclase VI increases left ventricular function in heart failure. Circulation 2004, 110:330-336.
7. Phan H.M., Gao M.H., Lai N.C., Tang T., Hammond H.K. New signaling pathways associated with increased cardiac adenylyl cyclase 6 expression: implications for possible congestive heart failure therapy. Trends Cardiovasc Med 2007, 17:215-221.
8. del Monte F., Harding S.E., Dec G.W., Gwathmey J.K., Hajjar R.J. Targeting phospholamban by gene transfer in human heart failure. Circulation 2002, 105:904-907.
9. Pathak A., del Monte F., Zaho W., Schultz J.E., Lorenz J.N., Bodi I., et al. Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1. Circ Res 2005, 96:756-766.
10. Szatkowski M.L., Westfall M.V., Gomez C.A., Wahr P.A., Michele D.E., DelloRusso C., et al. In vivo acceleration of heart relaxation performance by parvalbumin gene delivery. J Clin Invest 2001, 107:191-198.
11. Pleger S.T., Most P., Boucher M., Soltys S., Chuprun J.K., Pleger W., et al. Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue. Circulation 2007, 115:2506-2515.
12. Rengo G., Lymperopoulos A., Zincarelli C., Donniacuo M., Soltys S., Rabinowitz J.E., et al. Myocardial adeno-associated virus serotype 6-βARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation 2009, 119:89-98.
13. Ungerer M., Böhm M., Elce J.S., Erdmann E., Lohse M.J. Altered expression of β-adrenergic receptor kinase and β 1-adrenergic receptors in the failing human heart. Circulation 1993, 87:454-463.
14. Petrofski J.P., Koch W.J. The β-adrenergic receptor kinase (βARK1) in heart failure. J Moll Cell Cardiol 2003, 35:1167-1174.
15. Rockman H.A., Koch W.J., Lefkowitz R.J. Seven-transmembrane-spanning receptors and heart function. Nature 2002, 415:206-212.
16. Brodde O.E. Beta-adrenoceptors in cardiac disease. Pharmacol Ther 1993, 60:405-430.
17. Bristow M.R., Ginsburg R., Umans V., Fowler M., Minobe W., Rasmussen R., et al. β1- and β2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective β1-receptor down-regulation in heart failure. Circ Res 1986, 59:297-309.
18. Clapham D.E., Neer E.J. G protein beta gamma subunits. Annu Rev Pharmacol Toxicol 1997, 37:167-203.
19. Communal C., Singh K., Sawyer D.B., Colucci W.S. Opposing effects of β1- and β2-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein. Circulation 1999, 100:2210-2212.
20. Chesley A., Lundberg M.S., Asai T., Xiao R.P., Ohtani S., Lakatta E.G., et al. The β2-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through Gi-dependent coupling to phosphatidylinositol 3-kinase. Cir Res 2000, 87:1172-1179.
21. Zhu W.Z., Zheng M., Koch W.J., Lefkowitz R.J., Kobilka B.K., Xiao R.P. Dual modulation of cell survival and cell death by β2-adrenergic signalling in adult mouse cardiomyocytes. Proc Natl Acad Sci USA 2001, 98:1607-1612.
22. Lymperopoulos A., Rengo G., Koch W.J. Adrenal adrenoceptors in heart failure: fine-tuning cardiac stimulation. Trends Mol Med 2007, 13:503-511.
23. Packer M. The development of positive inotropic agents for chronic heart failure: how have we gone astrayβ. J Am Coll Cardiol 1993, 22:119A-126A.
24. Bristow M.R. β-adrenergic receptor blockade in chronic heart failure. Circulation 2000, 101:558-569.
25. Bristow M.R., Ginsburg R., Minobe W., Cubicciotti R., Sageman W.S., Lurie K., et al. Decreased catecholamine sensitivity and β-adrenergic receptor density in failing human hearts. N Engl J Med 1982, 307:205-211.
26. Harris C.A., Chuang T.T., Scorer C.A. Expression of GRK2 is increased in the left ventricles of cardiomyopathic hamsters. Basic Res Cardiol 2001, 96:364-368.
27. Yi X.P., Gerdes A.M., Li F. Myocyte redistribution of GRK2 and GRK5 in hypertensive, heart-failure-prone rats. Hypertension 2002, 39:1058-1063.
28. Dzimiri N., Muiya P., Andres E., Al-Halees Z. Differential functional expression of human myocardial G protein receptor kinases in left ventricular cardiac diseases. Eur J Pharmacol 2004, 489:167-177.
29. Martini J.S., Raake P., Vinge L.E., DeGeorge B., Chuprun J.K., Harris D.M., et al. Uncovering G protein-coupled receptor kinase-5 as a histone deacetylase kinase in the nucleus of cardiomyocytes. Proc Natl Acad Sci USA 2008, 105:57-12462.
30. Ungerer M., Kessebohm K., Kronsbein K., Lohse M.J., Richardt G. Activation of β-adrenergic receptor kinase during myocardial ischemia. Circ Res 1996, 79:455-460.
31. Choi D.J., Koch W.J., Hunter J.J., Rockman H.A. Mechanism of β-adrenergic receptor desensitization in cardiac hypertrophy is increased β-adrenergic receptor kinase. J Biol Chem 1997, 272:17223-17229.
32. Gros R., Benovic J.L., Tan C.M., Feldman R.D. G-protein-coupled receptor kinase activity is increased in hypertension. J Clin Invest 1997, 99:2087-2093.
33. Iaccarino G., Barbato E., Cipolletta E., De Amicis V., Margulies K.B., Leosco D., et al. Elevated myocardial and lymphocyte GRK2 expression and activity in human heart failure. Eur Heart J 2005, 26:1752-1758.
34. Hata J.A., Williams M.L., Schroder J.N., Lima B., Keys J.R., Blaxall B.C., et al. Lymphocyte levels of GRK2 (βARK1) mirror changes in the LVAD-supported failing human heart: lower GRK2 associated with improved β-adrenergic signaling after mechanical unloading. J Card Fail 2006, 12:360-368.
35. Bonita R.E., Raake P.W., Otis N.J., Chuprun J.K., Spivack T., Dasgupta A., et al. Dynamic changes in lymphocyte GRK2 levels in cardiac transplant patients: a biomarker for left ventricular function. Clin Transl Sci 2010, 3:14-18.
36. Inglese J., Freedman N.J., Koch W.J., Lefkowitz R.J. Structure and mechanism of the G protein-coupled receptor kinases. J Biol Chem 1993, 268:23735-23738.
37. Claing A., Laporte S.A., Caron M.G., Lefkowitz R.J. Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and β-arrestin proteins. Prog Neurobiol 2002, 66:61-79.
38. Pierce K.L., Premont R.T., Lefkowitz R.J. Seven-transmembrane receptors. Nat Rev Mol Cell Biol 2002, 3:639-650.
39. Koch W.J., Rockman H.A., Samama P., Hamilton R.A., Bond R.A., Milano C.A., et al. Cardiac function in mice overexpressing the β-adrenergic receptor kinase or a βARK inhibitor. Science 1995, 268:1350-1353.
40. Iaccarino G., Tomhave E.D., Lefkowitz R.J., Koch W.J. Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by β-adrenergic receptor stimulation and blockade. Circulation 1998, 98:1783-1789.
41. Rockman H.A., Choi D.J., Rahman N.U., Akhter S.A., Lefkowitz R.J., Koch W.J. Receptor-specific in vivo desensitization by the G protein-coupled receptor kinase-5 in transgenic mice. Proc Natl Acad Sci USA 1996, 93:9954-9959.
42. Akhter S.A., Eckhart A.D., Rockman H.A., Shotwell K., Lefkowitz R.J., Koch W.J. In vivo inhibition of elevated myocardial β-adrenergic receptor kinase activity in hybrid transgenic mice restores normal β-adrenergic signaling and function. Circulation 1999, 100:648-653.
43. Rockman H.A., Chien K.R., Choi D.J., Iaccarino G., Hunter J.J., Ross J., et al. Expression of a β-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc Natl Acad Sci USA 1998, 95:7000-7005.
44. Harding V.B., Jones L.R., Lefkowitz R.J., Koch W.J., Rockman H.A. Cardiac βARK1 inhibition prolongs survival and augments β blocker therapy in a mouse model of severe heart failure. Proc Natl Acad Sci USA 2001, 98:5809-5814.
45. Freeman K., Lerman I., Kranias E.G., Bohlmeyer T., Bristow M.R., Lefkowitz R.J., et al. Alterations in cardiac adrenergic signaling and calcium handling differentially affect the progression of cardiomyopathy. J Clin Invest 2001, 107:967-974.
46. Dorn G.W., Tepe N.M., Lorenz J.N., Koch W.J., Liggett S.B. Low- and high-level transgenic expression of β2-adrenergic receptors differentially affect cardiac hypertrophy and function in Gβq-overexpressing mice. Proc Natl Acad Sci USA 1999, 96:6400-6405.
47. Eckhart A.D., Fentzke R.C., Lepore J., Lang R., Lin H., Lefkowitz R.J., et al. Inhibition of βARK1 restores impaired biochemical β-adrenergic receptor responsiveness but does not rescue CREB(A133) induced cardiomyopathy. J Mol Cell Cardiol 2002, 34:669-677.
48. Jaber M., Koch W.J., Rockman H., Smith B., Bond R.A., Sulik K.K., et al. Essential role of β-adrenergic receptor kinase 1 in cardiac development and function. Proc Natl Acad Sci USA 1996, 93:12974-12979.
49. Rockman H.A., Choi D.J., Akhter S.A., Jaber M., Giros B., Lefkowitz R.J., et al. Control of myocardial contractile function by the level of β-adrenergic receptor kinase 1 in gene-targeted mice. J Biol Chem 1998, 273:18180-18184.
50. Matkovich S.J., Diwan A., Klanke J.L., Hammer D.J., Marreez Y., Odley A.M., et al. Cardiac-specific ablation of G-protein receptor kinase 2 redefines its roles in heart development and β-adrenergic signaling. Circ Res 2006, 99:966-1003.
51. Raake P.W., Vinge L.E., Gao E., Boucher M., Rengo G., Chen X., et al. G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure. Circ Res 2008, 103:413-422.
52. Zincarelli C., Soltys S., Rengo G., Rabinowitz J.E. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 2008, 16:1073-1080.
53. Zincarelli C., Soltys S., Rengo G., Koch W.J., Rabinowitz J.E. Comparative cardiac gene delivery of Adeno-Associated Virus Serotypes 1-9 reveals that AAV6 mediates the most efficient transduction in mouse heart. Clin Trans Sci 2010, 3:81-89.
54. Drazner M.H., Peppel K.C., Dyer S., Grant A.O., Koch W.J., Lefkowitz R.J. Potentiation of β-adrenergic signaling by adenoviral-mediated gene transfer in adult rabbit ventricular myocytes. J Clin Invest 1997, 99:288-296.
55. Akhter S.A., Skaer C.A., Kypson A.P., McDonald P.H., Peppel K.C., Glower D.D., et al. Restoration of β-adrenergic signaling in failing cardiac ventricular myocytes via adenoviral-mediated gene transfer. Proc Natl Acad Sci USA 1997, 94:12100-12105.
56. Williams M.L., Hata J.A., Schroder J., Rampersaud E., Petrofski J., Jakoi A., et al. Targeted β-adrenergic receptor kinase (βARK1) inhibition by gene transfer in failing human hearts. Circulation 2004, 109:1590-1593.
57. White D.C., Hata J.A., Shah A.S., Glower D.D., Lefkowitz R.J., Koch W.J. Preservation of myocardial β-adrenergic receptor signaling delays the development of heart failure after myocardial infarction. Proc Natl Acad Sci USA 2000, 97:5428-5433.
58. Shah A.S., White D.C., Emani S., Kypson A.P., Lilly R.E., Wilson K., et al. In vivo ventricular gene delivery of a β-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction. Circulation 2001, 103:1311-1316.
59. Emani S.M., Shah A.S., White D.C., Glower D.D., Koch W.J. Right ventricular gene therapy with a β-adrenergic receptor kinase inhibitor improves survival after pulmonary artery banding. Ann Thorac Surg 2001, 72:1657-1661.
60. Emani S.M., Shah A.S., Bowman M.K., White D.C., Emani S., Glower D.D., et al. Right ventricular targeted gene transfer of a β-adrenergic receptor kinase inhibitor improves ventricular performance after pulmonary artery banding. J Thorac Cardiovasc Surg 2004, 127:787-793.
61. Tevaearai H.T., Eckhart A.D., Shotwell K.F., Wilson K., Koch W.J. Ventricular dysfunction after cardioplegic arrest is improved after myocardial gene transfer of a β-adrenergic receptor kinase inhibitor. Circulation 2001, 104:2069-2074.
62. Tevaearai H.T., Walton G.B., Keys J.R., Koch W.J., Eckhart A.D. Acute ischemic cardiac dysfunction is attenuated via gene transfer of a peptide inhibitor of the β-adrenergic receptor kinase (βARK1). J Gene Med 2005, 7:1172-1177.
63. Chirmule N., Propert K., Magosin S., Qian Y., Qian R., Wilson J. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 1999, 6:1574-1583.
64. Brede M., Nagy G., Philipp M., Sorensen J.B., Lohse M.J., Hein L. Differential control of adrenal and sympathetic catecholamine release by β2-adrenoceptor subtypes. Mol Endocrinol 2003, 17:1640-1646.
65. Lymperopoulos A., Rengo G., Funakoshi H., Eckhart A.D., Koch W.J. Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure. Nat Med 2007, 13:315-323.
66. Lymperopoulos A., Rengo G., Gao E., Ebert S.N., Dorn G.W., Koch W.J. Reduction of sympathetic activity via adrenal-targeted GRK2 gene deletion attenuates heart failure progression and improves cardiac function after myocardial infarction. J Biol Chem 2010, 285:16378-16386.
67. Lymperopoulos A., Rengo G., Zincarelli C., Soltys S., Koch W.J. Modulation of adrenal catecholamine secretion by in vivo gene transfer and manipulation of G protein-coupled receptor kinase-2 activity. Mol Ther 2008, 16:302-307.
68. Rengo G., Leosco D., Zincarelli C., Marchese M., Corbi G., Liccardo D., et al. Adrenal GRK2 lowering is an underlying mechanism for the beneficial sympathetic effects of exercise training in heart failure. Am J Physiol Heart Circ Physiol 2010, 298:H2032-H2038.